Stella, MD-Led Platform

Stella is a menopause-focused telehealth company founded in the United Kingdom in 2019, where it became one of the leading digital menopause care providers in the National Health Service ecosystem. The company expanded to the United States market with a clinical model shaped by years of operating in a single-payer environment that demanded evidence-based protocols, outcome tracking, and cost-effectiveness — standards that inform how Stella approaches care delivery in the US insurance market. The platform's defining clinical feature is its comprehensive risk screening at intake. Before a patient's first appointment, Stella's digital intake assesses more than 65 risk factors across six domains: vasomotor symptoms (hot flashes, night sweats), genitourinary health (vaginal dryness, urinary symptoms), sleep, mood and cognition, cardiovascular risk, and musculoskeletal/bone health. This breadth reflects a clinical reality that is often missed in symptom-focused menopause consultations: the estrogen decline of perimenopause is a systemic hormonal shift that affects cardiovascular risk, bone density, mental health, and metabolic function simultaneously. By surfacing these dimensions before the first clinical visit, Stella's clinicians can offer a more comprehensive assessment than a standard 15-minute primary care appointment allows. In the United States, Stella has built in-network relationships with Aetna, Anthem, Blue Cross Blue Shield, and United Healthcare, making its specialist consultations accessible at standard copay rates for millions of commercially insured women. For patients whose plans are not in-network, Stella provides detailed superbills, and the platform recommends that patients with out-of-network benefits request reimbursement, citing typical reimbursement rates of up to 80% for out-of-network specialist visits. Stella clinicians can prescribe both hormonal and non-hormonal treatments, including FDA-approved estrogen and progesterone formulations, low-dose SSRIs and SSNRIs for vasomotor symptoms, and evidence-backed non-prescription interventions. The platform explicitly avoids compounded bioidentical hormones without FDA oversight, aligning with the Menopause Society's clinical guidance on HRT safety. Every clinical visit includes a 12-month subscription to the Stella app, which delivers educational content, symptom tracking, and peer community access — a recognition that menopause management benefits from sustained engagement rather than episodic clinical contact. The company expanded to the United States market with a clinical model shaped by years of operating in a single-payer environment that demanded evidence-based protocols, outcome tracking, and cost-effectiveness — standards that inform how Stella approaches care delivery in the US insurance market. The platform's defining clinical feature is its comprehensive risk screening at intake. Before a patient's first appointment, Stella's digital intake assesses more than 65 risk factors across six domains: vasomotor symptoms (hot flashes, night sweats), genitourinary health (vaginal dryness, urinary symptoms), sleep, mood and cognition, cardiovascular risk, and musculoskeletal/bone health. This breadth reflects a clinical reality that is often missed in symptom-focused menopause consultations: the estrogen decline of perimenopause is a systemic hormonal shift that affects cardiovascular risk, bone density, mental health, and metabolic function simultaneously. By surfacing these dimensions before the first clinical visit, Stella's clinicians can offer a more comprehensive assessment than a standard 15-minute primary care appointment allows. In the United States, Stella has built in-network relationships with Aetna, Anthem, Blue Cross Blue Shield, and United Healthcare, making its specialist consultations accessible at standard copay rates for millions of commercially insured women. For patients whose plans are not in-network, Stella provides detailed superbills, and the platform recommends that patients with out-of-network benefits request reimbursement, citing typical reimbursement rates of up to 80% for out-of-network specialist visits. Stella clinicians can prescribe both hormonal and non-hormonal treatments, including FDA-approved estrogen and progesterone formulations, low-dose SSRIs and SSNRIs for vasomotor symptoms, and evidence-backed non-prescription interventions. The platform explicitly avoids compounded bioidentical hormones without FDA oversight, aligning with the Menopause Society's clinical guidance on HRT safety. Every clinical visit includes a 12-month subscription to the Stella app, which delivers educational content, symptom tracking, and peer community access — a recognition that menopause management benefits from sustained engagement rather than episodic clinical contact.